Clinical trials: Relationship Distress

SARS-CoV-2 (COVID-19) Severe Pneumonia

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

• Completed
• Age: 18 to 75 years
• Phase 2
• Results posted

To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.

Trial name

NCT04412668

Testing

Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg

Where

10 sites in United States, Puerto Rico

Volunteers

36 people

Sponsor

aTyr Pharma, Inc.